Search

Displaying results 8321 - 8330 of 10000 in total
  1. Drug

    Olacaftor

    go.drugbank.com/drugs/DB16262
    Investigational

    Olacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis).

  2. Drug

    Olaparib-bodipy FL

    go.drugbank.com/drugs/DB16263
    Investigational

    Olaparib-bodipy FL is under investigation in clinical trial NCT03085147 (A Dye for the Detection of Cancer of the Tongue and Mouth).

  3. Drug

    Ontuxizumab

    go.drugbank.com/drugs/DB16270
    Investigational

    Ontuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1).

  4. Drug

    Pecavaptan

    go.drugbank.com/drugs/DB16279
    Investigational

    Pecavaptan is under investigation in clinical trial NCT03901729 (A Trial to Study BAY1753011 in Patients With Congestive Heart Failure).

  5. Drug

    Praliciguat

    go.drugbank.com/drugs/DB16300
    Investigational

    Praliciguat is under investigation in clinical trial NCT03254485 (A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (Hfpef)).

  6. Drug

    GSK-2981278

    go.drugbank.com/drugs/DB16319
    Investigational

    GSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis).

  7. Drug

    Seviprotimut-L

    go.drugbank.com/drugs/DB16328
    Investigational

    Seviprotimut-L is under investigation in clinical trial NCT01546571 (Study of a Melanoma Vaccine in Stage Iib, Iic, and III Melanoma Patients).

  8. Drug

    BGB-DXP593

    go.drugbank.com/drugs/DB16357
    Investigational

    BGB-DXP593 is a SARS-CoV-2 neutralizing antibody.

  9. Drug

    Autologous peripheral blood-derived CD34+ cells

    go.drugbank.com/drugs/DB16367
    ApprovedInvestigational

    Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. … [L27741] It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).

  10. Drug

    Matrix-M

    go.drugbank.com/drugs/DB16369
    Investigational

    Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax.